Drug Type Small molecule drug |
Synonyms Mito-MES, MitoQ, Mitoquinol + [3] |
Target |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC37H44O4P |
InChIKeyOIIMUKXVVLRCAF-UHFFFAOYSA-N |
CAS Registry444890-41-9 |
Start Date26 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Start Date03 Apr 2024 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lower Urinary Tract Symptoms | Phase 2 | US | 03 Apr 2024 | |
Overactive bladder syndrome | Phase 2 | US | 03 Apr 2024 | |
Hepatitis C, Chronic | Preclinical | NZ | 01 Mar 2007 | |
Parkinson Disease | Preclinical | AU | 01 May 2006 | |
Parkinson Disease | Preclinical | NZ | 01 May 2006 | |
Chemotherapy-induced damage | Preclinical | NZ | - | |
Friedreich Ataxia | Preclinical | NZ | - | |
Hepatitis C | Preclinical | - | - | |
Liver Cirrhosis | Preclinical | NZ | - | |
Neoplasms | Preclinical | NZ | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT05381454 (Pubmed) Manual | Phase 1/2 | 80 | tvtcrmtfzy(gmvluatcbq) = vtbwizhges isdeioccvt (taatvzwbpd ) View more | Positive | 07 Mar 2024 | ||
tvtcrmtfzy(gmvluatcbq) = tkhowrdrug isdeioccvt (taatvzwbpd ) View more | |||||||
Not Applicable | - | rvxfdiodnl(wdpuvjooyg) = novknvkqcj pnbcglbxjd (lfqqdepnev ) | Positive | 11 Nov 2014 | |||
Not Applicable | - | wpermmytye(cphdnisoof) = We also showed that adding MitoQ increased ATP after cold storage (24 hr) alone wuxsidfwnj (juuejyafiz ) View more | Positive | 05 Nov 2013 | |||
Cold storage + MitoQ (100 μM) |